A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers
Harmine HCl can be orally administered to healthy participants in doses <2.7 mg/kg with minimal or no AEs. Doses >2.7 mg/kg are associated with vomiting, drowsiness, and limited psychoactivity. This study is the first to systematically characterize the psychoactive effects of pharmaceutical quality harmine in healthy participants.
Authors
- Ronjon Banerjee
- Adolfo Garcı́a-Ocaña (ORCID: https://orcid.org/0000-0002-6883-6176)
- Robert J. DeVita (ORCID: https://orcid.org/0000-0002-2671-8497)
- James W. Murrough (ORCID: https://orcid.org/0000-0001-6286-1242)
- Rachel Fremont (ORCID: https://orcid.org/0000-0001-5285-7899)
- Geming Lu (ORCID: https://orcid.org/0000-0002-1322-3997)
- Jeremy N. Cohen (ORCID: https://orcid.org/0000-0001-8856-254X)
- Usha S. Govindarajulu (ORCID: https://orcid.org/0000-0001-5864-7403)
- Andrew F. Stewart (ORCID: https://orcid.org/0000-0001-7866-5959)
- Kunal Kumar (ORCID: https://orcid.org/0000-0002-1184-4837)
- Jessica L. Ables (ORCID: https://orcid.org/0000-0003-1818-3506)
- Peng Wang (ORCID: https://orcid.org/0000-0001-7854-1163)
- Hongtao Liu (ORCID: https://orcid.org/0000-0002-7840-9661)
- Olivia Wood
- L Israël
Institutions
- Discovery Institute (US)
- City of Hope (US)
- James J. Peters VA Medical Center (US)
- Mental Illness Research, Education and Clinical Centers (US)
- Center for Discovery (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1177/02698811241273772
- Citations
- 13
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.31
Funders
- American Foundation for Suicide Prevention
- AstraZeneca
- Hope for Depression Research Foundation
- University of Minnesota
- Wellcome Trust
- LivaNova
- Avanir Pharmaceuticals
- Usona Institute
- National Institutes of Health
- Allergan
- National Institute of Diabetes and Digestive and Kidney Diseases
- Janssen Pharmaceuticals